文献速递小儿泌尿与泌尿修复前列腺增生与排尿功能障碍

米拉贝隆联合治疗儿童难治性膀胱过度活动症:一项前瞻性开放标签研究

Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study.
PubMed 文献 · J Urol · 2016-11-30

这项前瞻性开放标签研究纳入35例对抗胆碱能药物难治或不耐受的特发性膀胱过度活动症患儿,在原有治疗基础上加用米拉贝隆。中位随访16.4个月,中位膀胱容量从预期容量的50%改善至74%(p<0.001),所有患儿控尿改善,其中12例完全干爽。7例报告轻中度副作用,2例因副作用或残余尿退出。作者认为加用米拉贝隆似乎是难治性患儿的安全选择。

要点

  • 35例难治性膀胱过度活动症患儿加用米拉贝隆,中位用药16.4个月。
  • 中位膀胱容量从预期容量的50%改善至74%(p<0.001)。
  • 所有患儿控尿改善(12例完全干爽),7例轻中度副作用,2例退出。

核心结论

  • 加用米拉贝隆似乎是难治性膀胱过度活动症患儿的安全替代选择。
  • 联合治疗耐受良好,调整剂量方案在这项首个儿科研究中似乎是安全的。

研究设计与样本

  • 前瞻性开放标签研究,采用超说明书加用米拉贝隆方案。
  • 纳入35例在强化行为与药物治疗下症状无改善和/或抗胆碱能药物加量时出现明显副作用的患儿。
  • 主要结局为疗效优于既往抗胆碱能药物单药治疗;次要终点为耐受性、安全性和满意度。
  • 通过排尿日记、残余尿、尿培养、心电图和生命体征评估疗效与耐受性;采用Wilcoxon符号秩检验进行统计分析。

主要发现

  • 患儿中位年龄10.3岁,加用米拉贝隆中位16.4个月。
  • 中位膀胱容量从预期膀胱容量的50%改善至74%(p<0.001)。
  • 所有患儿控尿改善,其中12例完全干爽。
  • 2例残余尿增加,报告1例尿路感染。
  • 7例报告轻中度副作用,2例退出(1例因副作用,1例因残余尿)。

临床怎么用

  • 作者认为,对于难治性膀胱过度活动症患儿,加用米拉贝隆似乎是安全的选择。
  • 作者认为,联合治疗耐受良好,调整剂量方案在这项首个儿科研究中似乎是安全的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Mirabegron (β3 adrenoreceptor agonist) is a new molecule with a mechanism of action distinct from antimuscarinics. Combination therapy with solifenacin was recently studied in an adult population. We evaluated the efficacy and safety of mirabegron as add-on therapy to treat urinary incontinence in children with idiopathic overactive bladder refractory/intolerant to antimuscarinics. MATERIALS AND METHODS: A prospective off-label study using add-on regimens of mirabegron was conducted in pediatric patients presenting with no symptom improvement while undergoing intensive behavioral and medical therapies and/or significant side effects while undergoing antimuscarinic dose escalation. Our primary outcome was better reported efficacy than with the use of prior antimuscarinic monotherapy. Secondary end points were tolerability, safety and satisfaction. Efficacy and tolerability were assessed based on voiding diaries, post-void residuals, urine cultures, electrocardiograms and vital signs. Families were questioned regarding continence, side effects and compliance. Wilcoxon signed-rank test was used for statistical analysis. RESULTS: A total of 35 patients were recruited at a median age of 10.3 years and were administered add-on mirabegron for a median of 16.4 months. Median bladder capacity improved from 50% to 74% expected bladder capacity (p <0.001). Continence improved in all patients, with 12 being completely dry. Post-void residual was increased in 2 patients and 1 urinary tract infection was reported. Seven patients reported mild or moderate side effects, with 2 withdrawals because of side effects (1 patient) and post-void residual (1). CONCLUSIONS: Add-on mirabegron appears to be a safe alternative for children with refractory overactive bladder. Dual therapy is well tolerated and adjusted dose regimen appears safe in this first pediatric study.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Morin F, Blais AS, Nadeau G, et al. Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study. J Urol. 2016. PMID: 27914999. doi:10.1016/j.juro.2016.11.101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。